Collost is a new generation sterile bioplastic collagen material with a fully preserved native structure, providing regeneration of damaged tissues.
The composition of the drug uses type I collagen, obtained from the skin of cattle, which is closest in biological composition and structure to human collagen. This is processed cattle dermis, the fibers of which resemble a lattice acting as a template for the formation of new tissue.
Collost acts in three main directions:
Firstly, when injected into the correction area, the effect of immediate mechanical filling of the space with the injected gel is observed.
Secondly, the injection of the drug causes an aseptic wound process in the intervention area, leading to the provocation of a response of the body in the form of stimulation of fibrillogenesis in the affected area.
Thirdly, Collost provides the correction area with the main biological resources required for wound healing - a natural, skin-tissue specific collagen resource. Collagen is the main protein involved in wound healing. When the implant binds to the wound, fibroblasts migrate to it from the surrounding tissues and invade the collagen implant. A transition matrix is created that stimulates the body's immune system and the activation of granulocytes, macrophages and fibroblasts, improves the transfer of growth factors released from cells, enhances the migration of fibroblasts and the proliferation of epithelial cells.
When Collost gel is administered, new collagen fibers are produced in the area of administration, filling the cavity in the implantation area, and the implant itself is gradually absorbed and replaced by its own autologous tissue.
Indications for use:
horizontal forehead wrinkles,
wrinkles above the bridge of the nose,
perioral wrinkles,
depression of nasolabial folds,
change in the volume and shape of the lips (with asymmetry, age-related depression of the lips, for aesthetic reasons)